Synlogic (NASDAQ:SYBX) Receives “Buy” Rating from HC Wainwright

Share on StockTwits

HC Wainwright reaffirmed their buy rating on shares of Synlogic (NASDAQ:SYBX) in a research report released on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on SYBX. Piper Jaffray Companies raised their target price on Synlogic from $15.00 to $16.00 and gave the stock an overweight rating in a research note on Wednesday, June 12th. Wedbush restated an outperform rating and issued a $20.00 target price on shares of Synlogic in a research note on Wednesday, June 12th. Jefferies Financial Group began coverage on Synlogic in a research note on Tuesday, April 30th. They issued a buy rating and a $18.00 target price for the company. Chardan Capital set a $20.00 target price on Synlogic and gave the stock a buy rating in a research note on Friday, April 12th. Finally, Zacks Investment Research upgraded Synlogic from a hold rating to a buy rating and set a $8.75 target price for the company in a research note on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $18.68.

Synlogic stock opened at $8.98 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.53 and a quick ratio of 11.53. The firm has a market cap of $233.59 million, a PE ratio of -4.42 and a beta of 2.31. Synlogic has a 1-year low of $5.75 and a 1-year high of $14.59. The stock has a fifty day simple moving average of $8.08.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.03. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.42 million. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%. As a group, equities research analysts forecast that Synlogic will post -2.16 EPS for the current year.

A number of hedge funds have recently modified their holdings of the stock. Alps Advisors Inc. raised its stake in Synlogic by 4.5% during the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock valued at $467,000 after buying an additional 2,658 shares in the last quarter. Bank of Montreal Can raised its stake in Synlogic by 5,743.1% during the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 12,520 shares in the last quarter. Geode Capital Management LLC raised its stake in Synlogic by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock valued at $1,087,000 after buying an additional 16,591 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Synlogic by 50.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock valued at $2,220,000 after buying an additional 105,628 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Synlogic by 1.2% during the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after buying an additional 2,005 shares in the last quarter. Institutional investors own 81.89% of the company’s stock.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: Guidelines for Successful Channel Trading

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SSE PLC/S  Receives Consensus Rating of “Hold” from Brokerages
SSE PLC/S Receives Consensus Rating of “Hold” from Brokerages
Zacks: Analysts Expect 3D Systems Co.  to Announce -$0.04 Earnings Per Share
Zacks: Analysts Expect 3D Systems Co. to Announce -$0.04 Earnings Per Share
James Hardie Industries plc  Receives Consensus Rating of “Hold” from Brokerages
James Hardie Industries plc Receives Consensus Rating of “Hold” from Brokerages
Zacks: Brokerages Anticipate CenterPoint Energy, Inc.  to Announce $0.33 EPS
Zacks: Brokerages Anticipate CenterPoint Energy, Inc. to Announce $0.33 EPS
Zacks: Brokerages Anticipate Community Health Systems  to Announce -$0.49 Earnings Per Share
Zacks: Brokerages Anticipate Community Health Systems to Announce -$0.49 Earnings Per Share
SYSCO Co.  Sees Significant Decrease in Short Interest
SYSCO Co. Sees Significant Decrease in Short Interest


 
© 2006-2019 Zolmax.